Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report)’s stock price rose 30.4% during trading on Monday . The company traded as high as $0.44 and last traded at $0.42. Approximately 1,777,419 shares changed hands during trading, an increase of 222% from the average daily volume of 551,506 shares. The stock had previously closed at $0.32.
Petros Pharmaceuticals Trading Down 8.0 %
The firm has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.47. The company has a market cap of $2.34 million, a price-to-earnings ratio of -0.05 and a beta of 2.12. The company has a current ratio of 1.40, a quick ratio of 1.26 and a debt-to-equity ratio of 0.71.
Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter. The firm had revenue of $1.42 million for the quarter.
Petros Pharmaceuticals Company Profile
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Recommended Stories
- Five stocks we like better than Petros Pharmaceuticals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Learn Technical Analysis Skills to Master the Stock Market
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The How And Why of Investing in Oil Stocks
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.